Francesco Tovoli

List of Publications by Citations

Source: https://exaly.com/author-pdf/6391184/francesco-tovoli-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

2,443
h-index

47
g-index

142
ext. papers

24
h-index

4
s-index

5.23
ext. citations

4
avg, IF
L-index

#	Paper	IF	Citations
103	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, e204564	13.4	274
102	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. <i>World Journal of Gastroenterology</i> , 2018 , 24, 3361-3373	5.6	203
101	Serological tests in gluten sensitivity (nonceliac gluten intolerance). <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 680-5	3	182
100	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040 <i>Journal of Clinical Oncology</i> , 2019 , 37, 4012-4012	2.2	136
99	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. <i>Journal of Hepatology</i> , 2018 , 68, 485-492	13.4	116
98	Microbiota, NASH, HCC and the potential role of probiotics. <i>Carcinogenesis</i> , 2017 , 38, 231-240	4.6	113
97	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. <i>Journal of Hepatology</i> , 2017 , 67, 173-183	13.4	106
96	Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness. <i>Cellular and Molecular Immunology</i> , 2013 , 10, 383-92	15.4	86
95	New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. <i>Gut</i> , 2018 , 67, 1674-1682	19.2	81
94	Deamidated gliadin peptide antibodies as a routine test for celiac disease: a prospective analysis. Journal of Clinical Gastroenterology, 2010 , 44, 186-90	3	79
93	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 160-168	6.1	58
92	Clinical and immunological features of celiac disease in patients with Type 1 diabetes mellitus. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011 , 5, 479-87	4.2	57
91	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , 2017, 86, 106-114	7.5	54
90	Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity. <i>BMC Gastroenterology</i> , 2014 , 14, 26	3	54
89	Clinical and diagnostic aspects of gluten related disorders. World Journal of Clinical Cases, 2015, 3, 275-	-8 4 .6	40
88	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. <i>Journal of Hepatology</i> , 2019 , 71, 1175-1183	13.4	35
87	Benefits, Open questions and Challenges of the use of Ultrasound in he COVID-19 pandemic era. The views of a panel of worldwide international experts. <i>Ultraschall in Der Medizin</i> , 2020 , 41, 228-236	3.8	34

(2017-2013)

Journal of Clinical Immunology, 2013 , 33, 1027-30	5.7	32	
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018 , 8, 9997	4.9	31	
Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013 , 7, 253-61	4.2	29	
Old and new serological tests for celiac disease screening. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010 , 4, 31-5	4.2	29	
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 403-414	4.9	28	
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. <i>European Radiology</i> , 2018 , 28, 3611-3620	8	26	
Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 538-54	6 ^{6.1}	26	
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. <i>Hepatic Oncology</i> , 2018 , 5, HEP01	4	24	
Experience with regorafenib in the treatment of hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211016959	4.7	24	
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020 , 15, e0232449	3.7	23	
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040 <i>Journal of Clinical Oncology</i> , 2020 , 38, 512-512	2.2	23	
A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	22	
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. <i>Digestive and Liver Disease</i> , 2019 , 51, 1067-1073	3.3	19	
Treatment of Combined Hepatocellular and Cholangiocarcinoma. <i>Cancers</i> , 2020 , 12,	6.6	17	
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040 <i>Journal of Clinical Oncology</i> , 2021 , 39, 269-269	2.2	17	
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2017 , 4, 129-137	4	15	
Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019 , 7, 69-77	5.3	15	
Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017 , 262, 179-184	3.1	14	
	Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Review of Gastroenterology and Hepatology, 2013, 7, 253-61 Old and new serological tests for celiac disease screening. Expert Review of Gastroenterology and Hepatology, 2010, 4, 31-5 Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. Journal of Cancer Research and Clinical Oncology, 2018, 144, 403-414 Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. European Radiology, 2018, 28, 3611-3620 Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors. Alimentary Pharmacology and Therapeutics, 2018, 48, 538-54 Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepatic Oncology, 2018, 5, HEP01 Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 17562848211016959 The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLOS ONE, 2020, 15, e0232449 Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040 Journal of Clinical Oncology, 2020, 38, 512-512 A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Digestive and Liver Disease, 2019, 51, 1067-1073 Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers, 2020, 12, Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040 Journal of Clinical Oncology, 202	Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Review of Gastroenterology and Hepatology, 2013, 7, 253-61 Old and new serological tests for celiac disease screening. Expert Review of Gastroenterology and Hepatology, 2013, 7, 253-61 Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. Journal of Cancer Research and Clinical Oncology, 2018, 144, 403-414 49 Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. European Radiology, 2018, 28, 3611-3620 Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free dietic beyond traditional metabolic factors. Alimentary Pharmacology and Therapeutics, 2018, 48, 538-546-1. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepatic Oncology, 2018, 5, HEPO1 Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 17562848211016959 The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449 Nivolumab (NIVO) + pillimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (AHCC): Subgroup analyses from CheckMate 040 Journal of Clinical Oncology, 2020, 38, 512-512 A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, Immunotherapy for hepatocellular carcinoma. A review of potential new drugs based on ongoing clinical studies as of 2019. Digestive and Liver Disease, 2019, 51, 1067-1073 Treatment of Combined Hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Digestive and Liver Disease, 2019, 51, 1067-1073 Treatment of Combined Hepatocellular carcinoma in cirrhosis and risk of false diagnosis of	Guchliver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Review of Gastroenterology and Hepatology, 2013, 7, 253-61 Old and new serological tests for celiac disease screening. Expert Review of Gastroenterology and Hepatology, 2010, 4, 31-5 Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. Journal of Cancer Research and Clinical Oncology, 2018, 144, 403-414 Hiter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. European Radiology, 2018, 28, 3611-3620 Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free dieti beyond traditional metabolic factors. Alimentary Pharmacology and Therapeutics, 2018, 48, 538-546-61. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepatic Oncology, 2018, 5, HEP01 Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 17562848211016959 The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLOS ONE, 2020, 15, e0232449 Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040 Journal of Clinical Oncology, 2020, 38, 512-512 A Relative Defricency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, 1067-1073 Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers, 2020, 12, 1060-1073 Treatment of Combined Hepatocellular and Cholangiocarcinoma and circles and risk of false diagnosis of hepatocellular carcinoma. United European Gastroenterology Journal, 2019, 7, 69-77 Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma acid lipase activity in cryptoge

68	Imaging of Colorectal Liver Metastases: New Developments and Pending Issues. <i>Cancers</i> , 2020 , 12,	6.6	14
67	Long term effects of gluten-free diet in non-celiac wheat sensitivity. Clinical Nutrition, 2019, 38, 357-363	B5.9	14
66	Rheumatoid arthritis: new monoclonal antibodies. <i>Drugs of Today</i> , 2018 , 54, 219-230	2.5	13
65	TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	12
64	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. <i>Vaccines</i> , 2020 , 8,	5.3	11
63	Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role. <i>Cancers</i> , 2020 , 12,	6.6	10
62	Regorafenib for the treatment of hepatocellular carcinoma. <i>Drugs of Today</i> , 2018 , 54, 5-13	2.5	10
61	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021 , 10, 370-379	9.1	10
60	Hepatocellular adenoma: An unsolved diagnostic enigma. <i>World Journal of Gastroenterology</i> , 2019 , 25, 2442-2449	5.6	9
59	Fibromyalgia and coeliac disease: a media hype or an emerging clinical problem?. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, S50-2	2.2	9
58	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. <i>Future Oncology</i> , 2017 , 13, 1893-1905	3.6	8
57	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020 , 15, 773-785	5	8
56	Contrast-Enhanced Ultrasound LI-RADS LR-5 in Hepatic Tuberculosis: Case Report and Literature Review of Imaging Features. <i>Gastroenterology Insights</i> , 2021 , 12, 1-9	2.1	8
55	Autoimmune liver disorders and small-vessel vasculitis: four case reports and review of the literature. <i>Annals of Hepatology</i> , 2014 , 13, 136-141	3.1	7
54	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016 , 3, 119-136	4	7
53	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021 , 41, 396-40	7 7.9	7
52	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00286	4.2	7
51	Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma. <i>Liver International</i> , 2018 , 38, 278-284	7.9	7

(2021-2017)

50	CEUS LI-RADS are effective in predicting the risk hepatocellular carcinoma of liver nodules. Digestive and Liver Disease, 2017 , 49, e22	3.3	6	
49	Nailfold Capillaroscopy in Primary Biliary Cirrhosis: a Useful Tool for the Early Diagnosis of Scleroderma. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 23, 39-43	1.4	6	
48	Autoimmune liver disorders and small-vessel vasculitis: four case reports and review of the literature. <i>Annals of Hepatology</i> , 2013 , 13, 136-41	3.1	6	
47	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018 , 38, 2028-2039	7.9	5	
46	Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. <i>Future Oncology</i> , 2018 , 14, 3049-3058	3.6	5	
45	Non-celiac gluten sensitivity: an emerging syndrome with many unsettled issues. <i>Italian Journal of Medicine</i> , 2014 , 8, 225	0.5	5	
44	Current guidelines for the management of celiac disease: A systematic review with comparative analysis <i>World Journal of Gastroenterology</i> , 2022 , 28, 154-175	5.6	5	
43	Lenvatinib mesylate to treat hepatocellular carcinoma. <i>Drugs of Today</i> , 2019 , 55, 305-313	2.5	5	
42	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13542	4.6	5	
41	Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver. <i>Magnetic Resonance Imaging</i> , 2021 , 75, 9-20	3.3	5	
40	Celiac Disease Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis. <i>Nutrients</i> , 2018 , 10,	6.7	5	
39	Ablation for hepatocellular carcinoma: beyond the standard indications. <i>Medical Oncology</i> , 2020 , 37, 23	3.7	4	
38	From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. <i>Histopathology</i> , 2018 , 72, 414-422	7:3	4	
37	Hereditary breast cancer: screening and risk reducing surgery. <i>Gland Surgery</i> , 2019 , 8, S142-S149	2.2	4	
36	Eosinophilic granulomatosis with polyangiitis of the major salivary glands: a case of sialadenitis in a young patient. <i>Internal Medicine</i> , 2013 , 52, 2131-4	1.1	4	
35	Autoimmune Hepatitis and Celiac Disease: Case Report Showing an Entero-Hepatic Link. <i>Case Reports in Gastroenterology</i> , 2010 , 4, 469-475	1	4	
34	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 477-492	5.3	4	
33	Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 244	8.1	4	

32	Telomerase reactivation is associated with hepatobiliary and pancreatic cancers. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020 , 19, 420-428	2.1	3
31	Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders <i>Cancers</i> , 2021 , 13,	6.6	3
30	An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib. <i>Drugs of Today</i> , 2018 , 54, 615-627	2.5	3
29	999P Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. <i>Annals of Oncology</i> , 2020 , 31, S695	10.3	3
28	Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery. <i>Hepatic Oncology</i> , 2020 , 7, HEP24	4	3
27	Artificial Intelligence: What Is It and How Can It Expand thelDltrasound Potential in the Future?. <i>Ultraschall in Der Medizin</i> , 2020 , 41, 356-360	3.8	3
26	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021 , 10, 126-136	9.1	3
25	Surrogate Markers for Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 215-217	0.7	2
24	Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting. <i>Autoimmunity Reviews</i> , 2021 , 20, 102787	13.6	2
23	What happened to my liver lesion (Hepatic Sclerosed Hemangioma)? Let's not forget (radiological) history. <i>Acta Gastro-Enterologica Belgica</i> , 2019 , 82, 554-555	0.6	2
22	Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention. <i>Hepatology</i> , 2017 , 65, 1075-1076	11.2	1
21	Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. <i>Liver Cancer</i> , 2020 , 9, 744-755	9.1	1
20	Sensitivity of autologous serum skin test for chronic autoimmune urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 958-9	4.6	1
19	Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3909-3914	3.3	1
18	An Uncommon Focal Liver Lesion: Intrahepatic Splenosis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 29, 257-262	1.4	1
17	Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 759-772	5.9	1
16	Anti-ganglioside antibodies and celiac disease. Allergy, Asthma and Clinical Immunology, 2021 , 17, 53	3.2	1
15	Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021 , 2, 45-53	0.8	1

LIST OF PUBLICATIONS

14	An update on atezolizumab for hepatocellular carcinoma. <i>Drugs of Today</i> , 2021 , 57, 365-375	2.5	1
13	Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for COVID-19 Pandemic. <i>Diagnostics</i> , 2021 , 11,	3.8	1
12	Nailfold capillaroscopy in primary biliary cirrhosis: a useful tool for the early diagnosis of scleroderma. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2014 , 23, 39-43	1.4	1
11	Unexpected newborns in the liver: hemangiomatosis onset after hepatic resection of a giant cavernous hemangioma. <i>Acta Gastro-Enterologica Belgica</i> , 2019 , 82, 454-455	0.6	1
10	Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. <i>Archives of Iranian Medicine</i> , 2013 , 16, 683-5	2.4	1
9	Thrombotic thrombocytopenic purpura mimicking an acute meningoencephalitis. <i>Acta Clinica Belgica</i> , 2011 , 66, 55-6	1.8	1
8	A case of inflammatory ascites. <i>Acta Clinica Belgica</i> , 2014 , 69, 204-7	1.8	0
7	Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster. <i>BMC Medical Genetics</i> , 2020 , 21, 225	2.1	O
6	Tocilizumab: From Rheumatic Diseases to COVID-19. Current Pharmaceutical Design, 2021, 27, 1597-160	073.3	0
5	More therapeutic alternatives for chronic idiopathic urticaria?. <i>Annals of Allergy, Asthma and Immunology</i> , 2008 , 101, 555; author reply 555-6	3.2	
4	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021 , 158, 133-143	7.5	
3	Role of nonalcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its role in patients[prognosis: A case-control study <i>Journal of Clinical Oncology</i> , 2019 , 37, 224-224	2.2	
2	Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: Validation study <i>Journal of Clinical Oncology</i> , 2017 , 35, e15684-e15684	2.2	
1	Evaluation of Toxicant-Associated Fatty Liver Disease and Liver Neoplastic Progress in Sprague-Dawley Rats Treated with Low Doses of Aflatoxin B1 Alone or in Combination with Extremely Low Frequency Electromagnetic Fields. <i>Toxins</i> , 2022 , 14, 325	4.9	